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ABSTRACT
Amino acids are important building blocks for the synthesis of a large number of
biologically active compounds and drugs. Amino acids with the pentacyclo-undecane (1)
and trishomocubane (2) frameworks fall into the class of conformationally constrained
non-natural amino acids. Conformationally constrained amino acids are found in many
naturally occurring, biologically active compounds. It was found that incorporating cage
structures into drugs induces a range of positive effects: promotes transport across the
cell membrane, drugs can be designed to target the central nervous system, increased
receptor site specificity, and retards metabolic degradation. In the light of this, it was
decided to investigate the incorporation of cage amino acids into peptides. A synthetic






Several chiral macrocyclic crown ethers and related analogues have been shown to be
capable of forming complexes enantioselectively with chiral organic ammonium salts.
The design and synthesis of host chiral macrocycles which are able to distinguish
between the enantiomers of guest organic ammonium salts is of interest in the areas that
include synthesis of enzymes, electrodes for specific ions or molecules, drugs targeted for
specific sites, and enantiomer separation. A synthetic procedure has been established for
the synthesis of cage annulated chiral crown ethers derived from amino acids. The
advantage of using cage compounds in crown ethers is due to increased rigidity,
increased solubility in non-polar solvents and increased chirality. Various techniques for
the determination of enantiomeric recognition have been studied and include NMR
spectroscopy, fluorescence emission spectroscopy and computational methods. The cage
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The aim of this study is to synthesise novel chiral crown ethers containing cage com-
pounds and to determine their enantiomeric recognition for chiral guest molecules. The
introduction will consist of (a) a general introduction to chirality, (b) a background of
chiral crown ethers, (c) motivation for the incorporation of cage compounds into chiral
crown ethers, and (d) a short overview of the synthetic approach followed in this study.
Chirality is a fundamental symmetry property of three-dimensional objects. An object is
said to be chiral if it cannot be superimposed upon its mirror image. Chiral is a deviation
of the Greek word chiros (hand). A carbon atom attached to four different groups is chi-










Enantiomers have identical chemical and physical properties in the absence of an external
chiral influence. This means that both will have the same melting points, solubility,
chromatographic retention time, infrared (IR) and nuclear magnetic resonance (NMR)
spectra. Enantiomers rotate plane polarised light in opposite directions. The notation
used is (+) for clockwise rotation and (-) for anti clockwise rotation. l
If the only difference between enantiomers were their rotation of polarised light, the
whole area of chirality would be relegated to little more than a scientific curiosity. That
is not so because all forms of life in nature are chiral and most of the important building
blocks which make up the biological macromolecules of living systems do so in largely
one enantiomeric form only [L-form].2,3 When, therefore a biologically active chiral com-
pound, such as a drug, interacts with a receptor site which is chiral, it should come as no
surprise that the two enantiomers of the drug interact differently and may lead to different
biochemical effects.4
A good example is the drug thalidomide for which both enantiomers have the same seda-
tive effect (calming or tranquillising) but only the (-)-enantiomer (2) causes foetal de-
formities. Who can forget the tragic consequences brought by this drug in the early
1960s? A high incidence of foetal deaths and malformations occurred due to its use by
pregnant women. Unfortunately even if the pure (+)-enantiomer had been used problems






Since then an enormous scientific drive to synthesise chiral molecules in optically active
form has been undertaken by many research groups.l,2,3,4,5 However, a large number of
biologically active compounds and pharmaceutical drugs are still synthesised as a race-
mic mixture either as a result of the lack of a chiral synthetic route or because of the high
cost of chiral synthesis.3,4,6,7 Resolving these mixtures involves enzymatic methods,8,9
chiral chromatography and in some cases fractional crystallisation with a co-chiral mole-
cule.4It is predicted that chiral crown ethers will playa major role in future enantiomeric
separations. 10
Cram synthesised the first chiral crown ether in 1972,11,12 and since then several other
chiral crown ethers have been synthesised.13,14,15,16,17,18,19,20 Several chiral macrocyclic
ligands and analogues have been shown to form enantioselective complexes with chiral
. . I 1921 222324 Th d' d h' f h' I horganIc ammOnIum sa ts. ' , " e eSIgn an synt eSIS 0 c Ira ost macrocycles
which are able to distinguish between the enantiomers of guest organic ammonium salts
is of interest to workers in areas such as catalysis,25,26 enzyme mimics,27,28 and enantio-
meric separation of racemic mixtures.29,30
Hayakawa31,32,33was the first to incorporate the pentacyclo-undecane (PCV, 3) unit into
crown ethers but their properties as ligands was not fully explored. The first chiral crown
ethers to incorporate the PCD unit was the binaphthol crown (4) synthesised in 1999 and
it showed promising enantioselectivity towards chiral ammonium salts.34
3 • 4
It has been predicted34 that the incorporation of the PCD framework into chiral crown
ethers will enhance their enantioselectivity by providing:
• a high degree of rigidity
• 10 extra chiral centres
• clear differentiation between the 2 faces of the ligand and
• increased solubility in non-polar solvents.
2
In order to test the validity of these predictions, it was decided to use the pyridine con-
taining macrocycles (5) synthesised by Bradshaw and Izatt et al.,35 as a model for the
synthesis of new pentacyclo-undecane (peU) containing crown ethers in this investiga-
tion. The synthesis of a new family of chiral PCU crown ethers, containing amino acids







The synthesis of two cage annulated a-amino acids containing the pentacyclo-undecane





The use of these amino acids in macrocycles is not feasible at this point since they exist
as racemates. The enantiomeric resolution of these compounds will be attempted in the
future with the use of enzymes.36,37,38 In the meantime, one of the aims of this investiga-
tion is to establish a procedure for incorporating amino acids 6 and 7 into peptides. The
difficulty of the esterification of the amino acid 6 has been attributed to steric hindrance39
and will be discussed in Chapter 2. It was therefore decided to attempt the coupling of
glycine onto the amino and carboxylic ends of 6 and 7 since it is the least sterically hin-
dered amino acid and it would also prevent the formation of diastereomers. In the light
of the huge steric bulk of cage amino acids, it will be a huge step forward to establish a
procedure to incorporate the amino acids 6 and 7 into peptides. The difficulties of incorp-
orating sterically hindered amino acids into peptides will be discussed in Chapter 3. Be-
ing successful in this regard will open the doors for future work on the synthesis of mac-
rocyclic peptides containing these cage amino acids.
3
CHAPTER 2
SYNTHESIS OF CAGE AMINO ACIDS
Amino acids are important building blocks for the synthesis of a large number of biologi-
cally active compounds and pharmaceutical drugs.
With the exception of l-aminocyc1opropanecarboxylic acid (8), found in cowberr/o and
cider apples,41 no other cyc10aliphatic aminocarboxylic acid occurs naturally.42 Many
. d4344 d df' . . 45 b Ihomologues of 8 have been synthesIse ' an teste or antI-tumor activIty ut on y
cycloleucine (9) was successful enough to make it to clinical trials.46 Cycloaliphatic a-
aminoacids of 2-amino-2-bornanecarboxylic acid (10) was shown to be actively trans-
ported by the transport system serving for the natural amino acids with apolar side
chains.47 They competitively inhibit the uptake of valine, leucine and methionine into










Conformationally constrained amino acids are also found in many naturally occurring
biologically active compounds e.g., alamethicin,49 a peptide antibiotic, is made up of
about 50% a-aminoisobutyric acid (AlB, 11) and a-ethylalanine (EtA, 12) which are
both considered to be sterically hindered amino acids. Other conformationally con-
strained amino acids, N-methylated a-amino acids (13),50,51 are found in cyclosporines,52









2-Aminoadamantane-2-carboxylic acid (15) was the first cage a-amino acid to be repor-
ted,42 and showed excellent anti-tumour activity but its lack of solubility (less than 1.5 x
. 10-3 mol dm-3) at physiological pH has prevented further biological evaluations. The
amino acid 15 was synthesised by subjecting adamantan-2-one (16) to a Bucherer-Lieb
synthesis to form the spirohydantoin 17, which was then hydroiysed.42 Amino acid 15 is
4
achiral and can therefore be used in peptide synthesis without forming diastereoisomers.
15
Reaction Scheme I: Synthesis of 2-aminoadamantane-2-carboxylic acid
In this study a hydantoin (14) route55.56.57was used for the synthesis of the amino acids
and it is noteworthy that some hydantoins, are themselves important medicinal and syn-
thetic compounds.
14
It has been shown58.59.60 that incorporating cage structures into drugs induces a range of
positive effects:
• increased lipophilicity promotes transport across cell membranes, therefore drugs
can now be designed to target the central nervous system.
• hydrocarbon moieties increase a drug's affinity for lipophilic regions in receptor
molecules.
• bulkiness retards metabolic degradation.
Derivatization of 15 to form dipeptides 18 enhanced their bio-availability by (a) increased
water solubility (b) increased transportation across tissue membranes, and (c) retardation





18a R = H, i-Bu
g;;j,,, CONHfHCOOH
NH2 R
18b R =H, i-Bu, CH2C~5
Since the introduction of amantadine (19)62 and 2-aminoadamantane-2-carboxylic acid
5
(15), considerable synthetic effort has taken place in the field of polycyclic com-
pounds.63,64,65 However, biological activity studies and the synthesis of target molecules
with potential biological activities have, to a large extent, been neglected. A number of
amino containing cage compounds (such as 20 and 21) with promising potential as an





It is clear from the discussion above that the availability of readily accessible amino acids












Reaction Scheme II: Synthesis of the PCU amino acid (6)
T~e synthesis. of \R)-(+)-8-aminopentacyclo[5.4.0.02,6.03,10.05,9]undecane_8_carboxylic
aCId (PCU-ammo. aCId, 6) was recently reported by Martins and co-workers as the first
6
peD related a-amino acid.73 They utilised a similar strategy as was used to obtain the
adamantane amino acid (15), namely conversion of a ketone to a hydantoin using
Strecker or Bucherer-Bergs reagents. Subsequently the hydantoin 24 is hydrolysed to its
corresponding amino acid. It was decided torepeat the synthesis of Martins et al.,73 since
it would serve as a valuable experience before attempting the synthesis the new TRIS
amino acid (7) mentioned in the introduction (vide supra).
Attempts to repeat synthesis of the hydantoin 24 under the relatively mild conditions re-
ported73 failed. In this investigation it was found that elevated temperatures and pres-
sures were required to ensure good yield of both hydantoin formation and hydrolysis of
the hydantoin to its corresponding amino acid. The reaction temperature was increased
gradually, i.e., 600e for 2 h, 900e for 2 hand l200e for 5 h. The synthesis of the peD
amino acid (6) is illustrated in Scheme II. Note that the synthesis of the monoketone 22
used for the synthesis of 6 will be discussed at the end of this chapter.
There are so far, no reports on the incorporation of the peD amino acid (6) into peptides.
Attempts to esterify 6 via various methods have proven to be unsuccessful, most probably
as a result of huge steric hinderance.39 In the light of the enormous steric bulkiness of the
peD amino acid (6), it would be a considerable challenge to incorporate 6 (or 7) into a
peptide.
A literature survey revealed that 4-amino-(D3Hrishomocubane-4-carboxylic acid (TRIS
amino acid, 7) had not been previously synthesised. Trishomocubanone (25) has D3
symmetry and has an advantage over the peD monoketone since only two hydantoin
isomers can potentially form compared to four possible hydantoin isomers in the case of
the peD monoketone (22). It should be noted that both the peD hydantion (24) and the
TRIS hydantoin (26) do not have a-hydrogens and racemization under basic conditions
can not occur, as is the case with many of the naturally occurring amino acids. Apart
from the advantage of less isomers, the functional groups on the TRIS amino acid (7) are
expected to be less sterically hindered, and therefore makes it an excellent candidate for
incorporating into peptides. Trishomocubanone (25) was converted to the TRIS amino
acid (7) as discussed for the peD amino acid (6) (scheme ill). Synthesis of the TRIS
monoketone 25 is discussed at the end of this chapter.
7
Reaction Scheme III: Synthesis of 4-amino-(D3)-trishomocubane-4-carboxylic acid (7)
Recrystallisation of the hydantoin 26 from tetrahydrofuran rendered a product of which
the CI mass spectrum exhibited a molecular ion at rn/z 230, confirming the desired hy-
dantoin formation. The infrared spectrum (p60) showed the presence of two carbonyl
absorption bands at 1766 and 1720 cm- 1 and two different N-H stretching vibration
absorption at 3314 and 3161 cm'l characteristic of a hydantoin ring. The IH NMR (p73)
spectrum of the hydantoin 26 recorded in deuterated dimethyl sulphoxide [(CD3hSO]
exhibited some resonance overlapping. The cage protons resonate between 1.0 - 3.0
ppm, and appeared as a complex signal pattern. The high field signals from 1.15 - 1.47
ppm are assigned to the four methylene protons, and the signals from 1.84 - 2.93 ppm to
the eight methine protons. Two deuterium exchangeable protons are registered at 7.89
and 10.55 ppm. The sharp resonance signal at 7.89 ppm can be assigned to the amide
proton and the broad signal registered at 10.55 ppm to the imide being shifted to a lower
field by the two adjacent carbonyl groups. The B C NMR (p74) of the hydantoin 26
exhibited two signals of carbonyl carbon atoms characteristic of an amide at 176.7 ppm
and an imide at 156.3 ppm.
Hydrolysis of the hydantoin 26 with sodium hydroxide at 150°C produced the TRIS
amino acid (7) in fair yield (60%). The infrared spectrum (p61) of 7 exhibited a broad
complex pattern of peaks between 2345 and 3630 cm- 1 typical of amino acids. A strong
carboxylate ion absorption peak appeared at 1579 em-I.
Further characterisation of 7 was done by forming the 9H-fluorene-9-methyl derivative







Recrystallisation from dichloromethane and hexane rendered a product for which the CI
mass spectrum (p68) exhibited a molecular ion at rn/z 430, confirming the desired
acylated amino acid. A ninhydrin test (Kaiser Test)74 was used to confirm the absence of
any primary amines. The infrared spectrum (p62) showed absorption at 3358 and 1710
em-I for the N-H of the secondary amide and the urethane carbonyl respectively. An
absorption band at 1510 cm- I for the urethane C-N bond gives further proof that the
amine group was acylated. The carbonyl of the carboxylic acid shows a strong
absorption peak at 1745 em-I. The IH spectrum (p7l) of Fmoc TRIS amino acid (27) in
(CD3hSO exhibited a complex pattern between 1.0 and 3.0 ppm characteristic of the cage
protons. Peaks between 7.2 - 8.2 ppm represent the aromatic protons of the Fmoc group.
A low field peak appeared at 12.1 ppm due to the carboxylic acid. The l3C NMR (p78)
showed two carbonyl carbon signals at 174.0 ppm for the acid and 155.4 ppm for the
amide. Two-methylene carbon resonances were registered at 31.8 ppm and 32.7 ppm for
the cage and one signal at 68.7 ppm for the CH2 of the Fmoc group. The Fmoc group is
base labile and a ninhydrin test indicated that some deprotection has occurred after three
weeks of storage.
Synthesis of monoketones 22 and 25 was performed according to established procedures
(Schemes IV and V). A Diels-Alder Reaction of p-benzoquinone (28) with cyclopentadi-
ene (29) resulted in formation of the adduct 30, which was photolysed to yield the cage
dione 31.75,76 Mono-protection of the dione using ethylene glycol in a Dean-Stark appa-
ratus to remove water afforded the monoketal 3277 which was subsequently reduced with
sodium borohydride to give the hydroxyketal 33.77,78 Hydrolysis of the ketal-protecting
group gave the keto-alcohol 34. which was converted via a modified Huang-MinIon re-
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Reaction Scheme IV: Synthesis of pentacyclo[5.4.0.02,6.03,10.05,9]undecane-8-ol (35)
The alcohol 35 was oxidised with chromium trioxide (Jones Oxidation) under acidic con-
ditions to form the monoketone 22.77 The alcohol 35 was then refluxed under strong
acidic conditions resulting in rearrangement of the cage skeleton to form the acetate 36.77
Hydrolysis of the acetate 36 to the trishomocubanol (37Yfollowed by Jones oxidation










Merrifield first reported solid-phase peptide synthesis (SppSf
9
in 1963, and since then
numerous methods of effecting coupling of amino acids have been investigated. The use
d·· 'd 80818283 ( d' I h I b d" 'd DCC)of acylating agents such as carbo lIml es ' " e.g. lCYC 0 exy car 0 llml e, ,
uronium [(benzotriazol-l-yl)-l, 1,3,3-tetramethyl uronium hexafluorophosphate, HBTD]84
and phosphonium [benzotriazol-l-yloxytris(dimethylamino) phosphonium hexafluoro
phosphate, BOP]85 salts, pre-formed anhydrides, active esters, and acid chlorides
86
,87 are
the most popular for simple amino acids. The efficient coupling of sterically hindered
amino acids like a-aminoisobutyric acid (Am, 11) and N-methylaminoisobutyric acid
(MeAm, 38) still proves to be difficult.88
11 38
Recent reports on the successful coupling of sterically hindered amino acids, such as 11
and 38 in solid phase peptide synthesis include the use of acid fluorides88,89,90,91,92 and





CFTPyBOP: R j =CFrOBt
N02-PyBOP: R 1=NOTOBt
CFT N02-PyBOP: R 1 =CFTNOTOBt
39
OBt: R2 ; R3 =H
CFTOBt: R2 =H; R3 = CF3
N02-OBt: R2 =H; R3 =N02
CFTNOTOBt: R2 = N02; R3 =CF3
As mentioned before (see Chapter 1), the TRIS amino acid (7) is expected to have less
steric hinderance compared to the PCD amino acid (6). It was also mentioned that all
reasonable attempts39 to esterify the PCD amino acid (6) failed, most possibly as a result
of steric hinderance. Incorporating the Fmoc TRIS amino acid (27) into short peptides
would therefore have a better chance of success. After establishing an effective proce-
dure, coupling of the PCD amino acid (6) into peptides might also be investigated.
It was decided to investigate the acid fluoride route for incorporating the Fmoc TRIS
amino acid (27) into a peptide since the use of BOP compounds 39 would require much








= Fmoc TRIS amino acid
Carboxylic acid fluorides have been prepared from potassium fluoride,95 potassium hy-
drogen fluoride,96 potassium fluorosulphinate,97 sulphur tetrafluoride,98 diethylene(2-
chloro-l, I ,2-trifluoroethyl) amine,99 thionyl fluoride loo and benzoyl fluoride. IOI The
most convenient method however, is the use of cyanuric fluoride in the presence of pyri-
dine. l02
Scheme VI outlines the route followed for the incorporation of the Fmoc TRIS amino
acid 27 into a peptide via solid phase synthesis techniques. The acid fluoride 40 was
synthesised in 90% yield by reacting 27 with one molar equivalents of pyridine and
cyanuric fluoride in dry dichloromethane. The infrared spectrum (p63) of 40 showed
strong absorption peaks at 1829 and 1724 cm- I for the carbonyl stretching vibrations of
the acyl fluoride and the urethane carbonyl, respectively. 13C NMR (p8I) showed that
the carbon a (68.6 ppm) to the fluorine being split with a coupling constant of 370 Hz,
and the ~ (174.0 ppm) carbon being split with a coupling constant of 55 Hz. The CI MS
was found to be 430.1818, which is consistent with a formula of C27H24N03F.
The TRIS amino acid (7) was obtained as a racemate (see chapter 2) and in order to avoid
the formation of diastereomeric mixtures it was decided to attach glycine (gly) onto both
the functional groups of the cage amino acid in proof that its sterical hindrance could be
overcome in SPPS. Since glycine is the least sterically hindered amino acid, it would
also be advantageous in coupling of the highly hindered Fmoc TRIS amino acid fluoride
(40). Glycine is also an achiral compound and will not form diastereomeric products
when coupled to a racemic amino acid. Fmoc glycine (41) was coupled to the p-benzyl-
oxybenzyl alcohol resin (Wang Resin/03,104 via a standard esterification method using
diisopropylcarbodiimide (DIPCDI) and hydroxybenzotriazole (HOBt).80,81,82,83 The Wang
Resin was chosen because it is the most economical and therefore most widely used of all
the resins available for Fmoc SPPS. The only disadvantage of using the Wang resin is
the lack of an amino group. Since it is functionalized with a hydroxyl group, it is not
possible to monitor the loading of the first amino acid with the use of the ninhydrin test
(Kaiser Test).84
The base labile Fmoc protecting group was removed by treating the resin with 20% Pipe-
ridine in dimethylformamide (DMF) for thirty minutes. The coupling of Fmoc amino
acid fluorides is normally carried out in the presence of base to trap the hydrogen fluoride
(HF) released,92,105,106 but can also be carried out in the absence of base with less effi-
ciency.88,I07 N,N-diisopropylethylamine (DIEA) is the base of choicel07 for coupling of
Fmoc amino acid fluorides but there is a danger of premature deblocking,108 especially in
the case of slow coupling reactions.92 Coupling of the Fmoc TRIS amino acid fluoride
13
(40) to the glycine containing resin 42, in the presence of one equivalent of DIEA,
showed a positive ninhydrin test (presence of primary amines) after six hours of reaction
time indicating that either premature deblocking had occurred or the reaction was incom-
plete. It was decided to investigate the use of pyridine as the HF scavenger since it is
used in the synthesis of the acid fluoride without any sign of deblocking. After six hours
of reaction time, the Kaiser Test was negative, indicating the completion of the coupling
reaction and no sign of premature deblocking. After twenty hours of reaction time, there
was still no sign of premature deblocking suggesting that pyridine is a better base for this
purpose. Some of the resin was treated with trifluoroacetic acid (TFA), after deprotec-
tion, to cleave the dipeptide 43 for analysis. Peptides are normally purified using prepa-
rative HPLC and the purity is determined with regular HPLC. This equipment was un-
fortunately not available during this study. Attempts to purify the peptide on a gravita-
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Standard cleavage procedures were used to confirm formation of the dipeptide 43 (see
experimental section). I3C NMR (p84) in methanol-d4 showed the presence of the cage
with two methylenes at 33.6 and 34.0 ppm, and eight methines from 42.9 to 55.3 ppm. A
methylene at 44.2 ppm indicates the presence of the glycine, and two quaternary carbons
at 171.5 and 176.3 ppm for the amide and carboxylic carbonyls respectively. HRMS
shows a signal at m/z 263 (M + H+) confirming the desired dipeptide 43.
The protecting group of the rest of the resin bound peptide was removed and the second
glycine was coupled to the cage via its Fmoc acid fluoride (44) in the presence of pyri-
dine. The tripeptide 45 was deprotected and cleaved from the resin, and proved to be
more difficult to purify than the dipeptide 43. HRMS (p69) of the crude product shows a
signal at m/z 320 (M + H+) confirming the presence of t~e desired tripeptide.
15
Even though a procedure has been established for incorporating cage amino acids into
peptide, it was not feasible to attempt the same reactions with the pev amino acid with-
out the use of HPLC. Future studies will focus on the incorporation of the pev amino
acid into a similar tripeptide. After successful coupling with glycine the optically pure
pev amino acid synthesised by Martins and co-workers73 can be used to establish proce-
dures to incorporate the pev amino acid into enantiomeric pure peptides containing other
naturally occurring amino acids via SPPS.
16
CHAPTER 4
SYNTHESIS OF CAGE ANNULATED CHIRAL CROWN ETHERS
Relatively few crown ethers containing a "cage" moiety as part of its "backbone" have
been synthesised. 109 Compounds 47110 and 48111 are examples of cage containing crown







An improved system of incorporating cage moieties into crown ethers using the PCD
cage diol53 was developed by Marchand et al. 109 The synthesis of 49109 is illustrated in
Scheme VII. The cage is now part of the ligand's backbone and not only serves as a rigi-
difying moiety but enables the bridgehead oxygen atom to participate, with the other do-














Reaction Scheme VII: Improved PCD cage annulated crown ether
17
In addition, the pentacyclo-undecane (PCD) cage renders the "faces" of the crown ether
inherently diastereotopically non-equivalent. Alkali metal picrate extraction experiments
on this type of crown ethers have shown109 that they are better hosts than their correspon-
ding non-cage annulated systems. Recently, Marchand et al.34 reported the synthesis of
the first PCD-cage annulated chiral crown ether 434 using a binaphthol group as the
source of chirality and was proven to exhibit promising enantioselectivity.
4
Many chiral agents are used in the synthesis of chiral macrocyclic ligands such as carbo-
hydrates,112.113 D-a-ephedrine,114 tartaric acid,115 cyclohexane-l ,2-diol,116 binaphthol,117
spirobifluorene.118 and amino acid derivatives.119
In this study it was decided to use amino acids because of their natural availability and
cost effectiveness. Note that the PCD unit is a meso compound but becomes chiral when
incorporated into a chiral crown. One of the main aims when designing the synthesis was
to get the chiral centres closer to the cage to take maximum advantage of the ten induc-
ible chiral centres (see structure 54)
54
From the past investigations, five rules have emerged which are regarded as being essen-
tial in estimating chiral recognition ability of a macrocyclic receptor and therefore used
as the basis of designing such systems.23
• in order to obtain good enantiomeric selectivity, the host and the guest need to form
stable diastereomeric complexes and the enantiomeric discrimination will depend on
the steric repulsion between the substituents at the chiral portions of the host macro-






larger chiral barrier(s) in a macrocycle usually results in an increase in the degree of
enantiomeric recognition, but it should not be too large as to prevent complexa-
t" 122,123,124,125IOn.
Still and co-workers l26 have shown that rigid diastereomeric complex between the
host and guest is essential for good enantiomeric recognition. If flexible complexes
form, the enantiomers can orientate themselves as to avoid the steric hindrance cre-
ated by the chiral centers. 119,121,127
The chiral macrocyclic compound should be stereochemically complimentary with
the guest enantiomers, interaction of the chiral centres should not be prevented by
" h" d 128129stene In rance. '
higher enantioselectivity is shown by macrocyclic li~ands possessing C2, C3 and D2
symmetry over those with C 1 or D3 symmetry.127,128,13
Incorporation of the pentacyclo-undecane (PCU) cage into a chiral macrocyclic ligands
would satisfy four out of the five requirements (vide supra). Chiral macrocycles containing
the PCU cage will have a C 1 symmetry, which may not be regarded as the most favourable
symmetry.127,128,130 Though chiral crown ethers of type 54 possesses a C. symmetry, we
anticipate that the cage would offer:
• 10 extra chiral centers when associated with a source of chirality.
• high degree of rigidity.
• clear differentiation between the 2 faces of the ligand and,
• increased solubility in non-polar solvents, which might enable such a macrocycle to
show increased enantiomeric recognition.
The pyridine containing macrocycles131,132,133,134,135,136,137 55 and 56 were chosen as the
model systems for this study in order to obtain a good comparison between the cage mac-
rocycles and other relatively rigid systems. Systems 55 and 56 have been shown to form
strong complexes with ammonium salts, via NMR and fluorescence studies respec-











The novel cage macrocyclic analogues 57 and 58 were intended to be synthesised in this
study. The use of phenylglycine derivatives as a source of chirality in these systems has
shown less promising complexation with NMR studies. It was however decided to use
phenylglycine in this study of new chiral PCO macrocycles in order to be able to apply
and learn the technique of complexation studies using Fluorescence Spectroscopy which
was recently reported138 to be an easy tool for determining enantiomeric recognition of
macrocycles. Three model systems were chosen that would allow for Fluorescence
Spectroscopy studies138 on the corresponding PCD cage analogues. The discussion on









Reaction Scheme VIII: Synthesis of chiral pyridine macrocycle 55132
20
The PCV cage is substituted for the rigid pyridine unit in the model compounds 55 and
56. Synthesis of model crown, (4S, 14S)-(-)-4, 14-diphenyl-6,9,12-trioxa-3,15,21-triaza-
bicyclo[ 15.3.1 ]heneicosa-1 (21),17, 19-triene-2, 16-dione (55), is shown in
Scheme Vill.132 Ring closure with diacid dichlorides and diamines is usually an effective
method to form cyclic macrocyclic diamides139,140,141 but the yield reported is relatively
low (16%).
It was decided to follow a similar route for the synthesis of the corresponding PCV mac-
rocyle 57, but with slight modification of the reaction conditions in hope of achieving a
better yield. Scheme IX outlines the route followed for the synthesis of the PCV macro-
cycle 57 as corresponding PCV cage analogue.
The reaction of the PCV-8,1l-dione (31) with excess allylmagnesium bromide (obtained
from reacting allylbromide with magnesium in ether) afforded the corresponding endo-
8,endo-11 diol 51 (91 %).142,143 Subsequent dehydration of the diol 51 produced the cor-
responding hexacyclic ether, 52.144 Ozonolysis of the diene followed by an oxidative
work-up gave the PCV-diacid 59 (76%). The lH NMR showed an AB pattern at 1.45 and
1.83 rpm with a coupling constant of 10 Hz indicating the presence of the PCV cage.
The I C NMR (p90) showed a triplet at 42.8 ppm which is characteristic of the methylene
on the cage. A triplet at 37.9 ppm represents the methylene joining the carboxylic acid to
the cage and a singlet at 171.4 ppm for the carbon of the carboxylic acid.
TsOH
52
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Reaction Scheme IX: Synthesis of macrocycle (R)-57
The diacid 59 was subsequently reacted with oxalylchloride to form the diacyl chloride
60 and used directly in the next step. (R)-(+)-2-phenylglycine methyl ester (61) was re-
duced using LiAlfu in THF to (R)-2-phenylglycinol (62) in 67% yield after recrystallisa-
tion from toluene. 145 The diamine 63 was prepared in 65% yield by treating two equiva-
lents of (R)-2-phenylglycinol (62) with one equivalent of diethylene glycol ditosylate
(obtained by reacting diethylene glycol and tosyl chloride in aqueous potassium hydrox-
ide) in the presence of sodium hydride in THF.146 The alkoxide of the aminoalcohol
formed under these conditions, acts as the nucleophile. It was difficult to obtain pure
diamine 63 and hence it was used as obtained in the next step.
The coupling of the peD diacyl chloride 60 and the diamine 63 was performed in pure
and dry toluene, with triethylamine as the base, to give the macrocycle (R)-57 (37.5%).
The increase in yield as compared to the model compound 55 is perhaps a combination of
two factors; (i) the reaction was carried out at a much higher dilution (2 mmol dm,3) and
(ii) because the cage diacyl chloride 60 is much more rigid and helps in tying up the loose
ends of the diamine 63. The crude product was purified by chromatography and recrys-
tallised from toluene. The infrared spectrum (p64) of 57 showed multiple peaks from
3307 - 3343 cm'l representative of secondary amide NH stretching and a peak at 1517
cm'l representing secondary amide NH bending. A characteristic CO stretching vibration
peak at 1674 cm'l confirmed the amide group. IH NMR (p91) shows an AB pattern at
1.49 and 1.82 ppm with a coupling constant of 10 Hz and a complex multiplet from 2.15
to 2.80 ppm representing the peD cage. Another complex multiplet from 3.45 to 3.95
22
ppm indicates the presence of the OCH2 protons. The aromatic protons exhibited a
multiplet from 7.12 to 7.53 ppm. I3C NMR (p92) of 57 showed eleven signals for the
cage carbons (unlike in the regular cage annulated crowns and chiral crown 50 reported
by Marchand et al.,34 which showed only six signals for the cage carbons). The lack of
symmetry on the cage part of 57 indicates that the positioning of the chiral agents
(phenylglycinol (62)) successfully induced chirality on all ten of the inducible carbons of
the cage. The CI MS (p70) confirms the [1: 1] cyclization product with a m/z peak at
585.2973 and supports a formula of C3sH41N206.
The synthesis of the dipyridine crown 56, is outlined in Scheme X and has been shown,
via Fluorescence Spectroscopy studies, to exhibit good enantiomeric discrimination for









Reaction Scheme X: Synthesis of dipyridine macrocycle 56138
65
The method used in literature138 to prepare 56 was employed for synthesising the novel
macrocycle 58 as the corresponding cage analogue. The key intermediate 65 was pre-
pared from condensation of benzyloxycarbonyl-L-proline and 2,6-bishydroxymethyl
23
pyridine (scheme X) in the presence of dicyclohexylcarbodiimide (DCC) and N,N-
dimethylaminopyridine (DMAP) followed by deprotection. Acylation of the chiral
diamine dihydrobromide 65 with PCU diacyl chloride (60), under various conditions did
not result in the desired [1: 1] cyclization product 58, shown in Scheme XI. This may be
attributed to steric effects from the relatively rigid proline system; The diamine dihydro-
bromide 65 was dissolved in a mixture of dichloromethane and triethylamine and then
reacted with 60. In the second method, toluene was used as the solvent in an attempt to
decrease the polarity of the medium to slow the reaction down. In the third method, the
free diamine (obtained by treating a solution of 65 in dichloromethane with triethylamine
and then washed with water) was reacted with 60 using toluene as the medium. All three
methods proved unsuccessful in synthesising the macrocycle 58 possibly as result of
aforementioned steric reasons.






. 1. CHzClz / N(Eth
2. Toluene / N(Eth
3.60
58
Reaction Scheme XI: Attempted synthesis of the chiral macrocycle 58
It was decided to synthesise the PCU containing macrocycle 66 instead, since phenylgly-
cine will be used as the source of chirality rather than the more sterically hindered pro-
line. It would also enable us to compare 66 and 57 since they both have just two amide
groups as compared to the two additional ester groups in 58.
The synthesis of macrocycle 66 is outlined in Scheme XII. Macrocycle 66 is similar to
57 (Scheme IX), only differing by the presence of a pyridine moiety as part of the ring.
The diamine 67 was prepared in 72% yield by treating two equivalents of (S)-2-phenyl-
glycinol with one equivalent of pyridine dibromide in the presence of sodium hydride in
THF.
137
The diamine 67 was difficult to purify and used as obtained in the next step. The
infrared spectrum (p65) of 67 showed peaks between 3025 and 3370 cm- I for the primary
amines, and peaks at 1104 cm'l for the ether groups. The IH NMR (p95) showed a
singlet at 1.91 ppm for four D20 exchangeable protons indicating the presence of the
24
diamine. A multiplet at 3.59 ppm represented the four OCHz protons and a pair of
doublets at 4.25 and 4.29 ppm for the two-methine protons at the chiral centre. A singlet
at 4.65 ppm is for the four protons of the methylene group attached to the pyridine. The
l3C NMR (p96) showed peaks for a methine at 55.4 ppm and two methylene peaks at
73.9 and 77.1 ppm. CI MS (p72) confirmed the compound with a rn/z peak at 378.2175.
Coupling of the PCU diacyl chloride (60) and the diamine 67 was performed in pure and
dry toluene, with triethylamine as the base, to give the novel crown 66 (24%). The infra-
red spectrum of 66 showed broad peaks from 3294 to 3425 cm- I representative of secon-
dary amide NH stretching and a peak at 1523 cm- I representing secondary amide NH
bending. A characteristic CO stretching vibration peak at 1656 cm- I confirms the presen-
ce of an amide bond. A broad peak at 1116 cm- I is indicative of the CO stretching vibra-
tions of the ether linkages. I H NMR showed an AB pattern at 1.40 and 1.75 ppm with a
coupling constant of 10.6 Hz and a complex multiplet from 2.22 to 2.74 ppm representing
the PCU cage. Another complex multiplet from 3.80 to 4.00 ppm indicates the presence
of the OCHz protons. A triplet at 4.66 ppm with a coupling constant of 14.3 Hz is regis-
tered for the methylene protons bonded to pyridine. The aromatic protons are found as a
multiplet from 7.12 to 7.44 ppm. One of the two NH protons registered as a doublet at
7.79 ppm with a coupling constant of 7.7 Hz and the other proton was masked with one
of the pyridine protons between 7.62 and 7.74 ppm. The CI MS confirms the [1: 1] cycli-













Reaction Scheme XII: Synthesis of macrocycle 66
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CHAPTERS
ENANTIOMERIC RECOGNITION STUDIES OF CHIRAL MACROCYCLES
Many methods exist for enantiomeric recognition studies and include fast atom bom-
bardment mass spectrometry (FABIMS),147 fourier transform ion cyclotron resonance
148 IH NMR 149 d flmass spectrometry (FfICRlMS), low temperature ,an uorescence spec-
troscopy.138 The extent of enantiomeric recognition displayed in these types of studies
was found to parallel separation factors demonstrated by chromatographic meth-
OdS. 23,IS0,lSl,lS2,lS3,lS4,lSS,lS6,lS7 Computational chemistry is a theoretical method which has
been applied to a limited extend34,133,136 in order to calculated the stability of host-guest
complexes. It is important to note that a literature survey showed application of mostly
one, if any, of the analytical techniques combined with extraction or transport studies.
Extraction or transport studies make use of V or W-tube experiments.1l7 A single study of
MS, NMR, fluorescence, computational techniques in relation to extraction studies have
not yet been reported. Most of the chiral recognition studies focussed only on one of the
techniques mentioned above and a lack of calibration methods between these techniques
is apparent. It should also be pointed out that good chiral discrimination alone may not
be sufficient proof of successful chiral separation by extraction or transport techniques,
since complexation might still be too weak for phase transfer or too strong for releasing
of the guest. The aim of this chapter is to provide a short overview on the theory and pro-
cedures of some of the methods used to determine enantiomeric recognition.
5.1. Extraction Studies with V and W tube
a-arm ~-arm
+--_~ excess R guestracemic guest in H20 ......~-+-





A racemic solution of guests in an aqueous phase (a-arm) form a complex with the host
in an organic phase (CHCI 3) at the solvent interface and is transferred into the organic
phase. Subsequent transport to the other side of the V or W-tube enables releasing of the
guest to the second water phase (~-arm). If the rate (k1) of transport of R-guest is larger
that of S-guest, then after some time, the optical activity of the second aqueous phase will
indicate enantiomeric excess for R-guest. In a V-tube the enantiomeric excess will de-
crease with time since equilibrium will ultimately be obtained. In a W-tube with R-host
in one side of the W-tube and S-guest on the other side, a racemic mixture of guest in the







racemic guest in H20








At the solvent interface of the reservoir, an equilibrium is built up for the complexation
between host (H) and guest (G) and is expressed as ('*' indicates organic phase):
G+ + X· + H* ~ GX*.H* (1)
The complex reaches equilibrium in the organic phase and is expressed as:
GX*.H* ~ G* + X* + H* (2)
Transportation is said to have occurred when the guest (G) and counter ion (X) is re-
leased into the collecting arm. An equilibrium is established at the delivery arm for the
complex and is expressed as:
GX*.H* ~ G+ + X· + H* (3)
In the left side of the W-tube, S-guest is transported faster than R guest to the left arm.
Some R guest will be transported as well. After some time, the left arm will become en-
riched with the R guest as the S guest is transported back to the racemic reservoir (centre
of the tube). With increased time, the enantiomeric excess in each arm will increase. 1l7
5.2. Low Temperature IH NMR Studies
NMR line-shape methods are a valuable tool for studying a variety of processes that be-
come slow on the NMR time scale at temperatures between room temperature and
- 90°c.149,158 Reinhoudt and de long have discussed159 the specific application of NMR
line-shape methods to the determination of rate constants and activation energies for the
dissociation of crown ether complexes. The concept can be explained using Figure 3. In
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the absence of complex formation, protons Ha and Hb are indistinguishable on a NMR
spectrum. When complex formation occurs, the proton on the same side of the crown as
the alkyl group of the alkyl-ammonium salt experiences a different magnetic environment
than the proton on the opposite side. At ambient temperatures, the rate of complexation
and dissociation is so rapid on the NMR time scale that only an average chemical shift of
the protons is observed. Lowering the temperature of the NMR probe, "freezes" com-
plexes that have high activation energies for dissociation (Le. more stable complexes).
This slows down the exchange rate on the NMR time scale resulting in the observation of
different signals for Ha and Hb.
Figure 3: Ammonium ion complexation in a macrocycle
The rate of the dissociation process is thought to be the rate-determining step and can be
expressed as:
kc =1t Av / 2 1/2 (1)
Where kc is the rate of the exchange process at the coalescence temperature (temperature
at which the signals just merge) and I1v is the chemical shift separation (Hz) between the
resolved signals. 160 The free energy of activation at the coalescence temperature (AG;te)
can be calculated from the rate constant (ke), the molar gas constant (R), the coalescence
temperature (Te), Planck's constant (h), and the Boltzmann constant (K) using equation
2.160
(2)
Greater enantiomeric resolution is observed when the difference in the free energies be-
tween the two isomers, 11 (I1G), is maximised and the I1G is minimised.149 Stronger com-
plexation between host and guest will require a lower coalescence temperature (ke) and
therefore result in a lower free energy (I1G).
This procedure of calculating free energy values for different complexes requires a vast
amount of time on a NMR instrument mainly due to continuously changing the tempera-
ture of the probe.
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A qualitative measure of the enantiomeric recognition can be obtained from the lH spec-
tra of the diastereomeric complexes with the use of equations 3 and 4.
161
[(R)G,(SS)H]/[(S)G,(SS)H] =(Os" -02RS")I( 02RS" - OR") (3)
The relative concentrations of the diastereomeric complexes formed by the (R) and (S)
guests [(R)G and (S)G] with the (S,S)-host [(SS)H] are obtained from the chemical shifts
(OSH, ()RH and <hRSH) of a selected host signal 'in the presence of one equivalent of (S)-
guest, one equivalent of (R)-guest, and two equivalents of (R,S)-guest respectively. cSS
SG
and ()2RSSG are the chemical shifts of a selected (S)-guest signal in solutions containing
the host and one equivalent of (S)-guest and two equivalents of (R,S)-guest respectively,
()RSG and ()2RS RG have the same significance for the (R)-guest signals, and OFG is the corre-
sponding chemical shift for the uncomplexed guest. 161
This type of experiment is performed at one set temperature and therefore requires less
time on a NMR spectrometer and can be used as a preliminary test for complexation.
IH NMR (300 MHz) spectra of one equivalents of (R)-u-methylbenzylammonium hy-
drochloride (68) and (S)-u-methylbenzylammonium hydrochloride (69) in solution
(CDC!)) with macrocycles 57 and 66 were obtained at 20, a and -20°e. It was not feasi-
ble to go to any lower temperatures since it would require longer instrument time and a
more expensive NMR solvent (CD2Cb).
None of the spectra (p 102-1 05) showed any significant change in chemical shifts between
the free hosts (57 and 66), and the mixtures of the hosts and guests (57 + 68, 57 + 69, 66
+ 68 and 66 + 69). If any complexation were to occur then protons at the chiral centre
would be expected to split the most. It is obvious that there is no sign of complexation,
let alone any enantiomeric discrimination. It can be concluded from this observation that
either the macrocycles 57 and 66 are poor hosts or, that -20oC is not a low enough






Macrocycle 4 has been shown34 via transport experiments to be selective for (S)-a-
methylbenzylamine (69). IH NMR spectra (pIOO-IOI) of 4 with 68 and 69 at -20°C
shows a change in the chemical shifts of some protons of the binaphthyl group (2.4 ppm
and 7.9-8.0 ppm), indicating the formation of a complex. There was no notable
differentiation between the spectra of the two diastereomeric complexes (4 + 68 and 50 +
69). Since it has been proven in literature34 that the host 4 transported (S)-a-
methylbenzylamine in enantiomeric excess, it is clear that -20°C is also not low enough
to show enantiomeric discrimination. It was reported that only 12% of guest (3 times
excess with respect to host) were transported (4 hours) which might indicate that the
activation energy for the dissociation of the complex might be high.
4
It is clear that in order to practice this exercise, it is important to use CD2Cb (m.p. -90°C)
rather than CDC!] (m.p. -50°C) as solvent in order to experiment at lower temperatures,
and to have access to a NMR instrument for long periods at a time.
5.3. Fluorescence Spectroscopy Studies
Recently, Hua, 2000, reported the use of fluorescence spectroscopy in determining enan-
tiomeric recognition. 138 With this technique,138 fluorescence emission was measured for
hosts and for mixtures of hosts and guests, and the difference in wavelength at maximum
intensity (~A) between the two diastereoisomers was taken as a measure of enantiomeric
discrimination. Stronger complexation between host and guest would result in greater
significant change in configuration of the molecules and therefore a larger change in the
wavelength (50 nm) at maximum intensity (AmaJ.
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Solutions, 1 x 10-3 molar, of 57 with 68, 69, 70, 71, 72, 73 in 1:3 metha-
nol:dichloromethane were excited at 257 nm and the fluorescence emission recorded.
The excitation wavelength was determined by finding the maximum wavelength the so-
lution absorbed when subjected to ultra Violet radiation. There was no change in Amax
between the pure macrocycle 57 and mixtures of the macrocycle with the various guests.
Similar experiments were done using macrocycles 66 (excitation wavelength = 278nm)
and 4160 (excitation wavelength = 307 nm) and even these showed no sign of
conformational change. It can be concluded from these results that either no
complexation had occurred or that there is no significant conformational change in these
systems upon complex formation. These measurements were performed at room











(R)-phenylglycine methyl ester (73)
Computational chemistry due to spectacular advances in both hard and software162 has
become a valuable tool to enhance our understanding about many complex chemical
systems. There are three areas of computational tools available. Molecular mechanics or
force field derived calculations, semi-empirical methods and ab initio calculations. Mo-
lecular mechanics are typically used for very large biochemical systems such as proteins
and although it is the cheapest method in regard to computer time, good force fields for
macrocyclic hosts with ammonium ion guest interactions have not yet been developed.
In general molecular mechanics also give the least accurate results. 163 Molecular me-
chanics results of such systems gave meaningless geometry. 164
The cheapest ab initio calculation (in respect of computer time) that would give a reason-
able answer is a Restricted Hartree-Fock (RHF) calculation with the 3-21+0 basis set.
Diffuse functions (+) are used to give a better description of systems containing pi elec-
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trons and lone pairs. One of these calculations takes between 3 and 5 days on a super-
computer (SGI Origin 2000 with 64 CPU's, 20GB of RAM and huge disc space - note
that due to limitations of the Gaussian 98 code, little gain in performance is obtained us-
ing more than 2 CPU's in parallel calculations). In the light of the 40 calculations per R
and S host with Rand S guest, a study using ab initio calculations would have taken sev-
eral years to complete.
The only alternative option is to use semi empirical calculations, provided that the
answers obtained are reliable enough. This was verified in our laboratoryl64 by compar-
ing PM3 semi empirical results of such a system with the RHF/3-21 +G ab initio results
of the same system. The route of mean square (RMS) overlay error of the PM3 result
with the ab initio result is about o.oIA, which is very acceptable. The average time for
PM3 calculations of these systems takes between 2 and 9 hours.
Geometry optimisations of the ligands 57 and 66 with guests 68, 69, 70, and 71 were
done using Gaussian 98 at a PM3 semi-emperical level of theory. Starting geometries of
the complexes were drawn in Chern 3D and converted to Gaussian input files.
Host molecules containing the PCU cage present two potential complexation "faces" to
an approaching guest molecule. As the host-guest complex formation progresses, the
guest can pursue either a "topside" approach i.e., along a trajectory proximal to the meth-
ylene carbon of the cage moiety, or a "bottomside" approach in which the approaching
guest follows a trajectory that lies distal to the methylene carbon atom in this moeity.34
"topside" approach
"bottomside" approach
Figure 4: Designation of topside and bottomside in PCU crown ethers
The guest molecule was placed at a distance of about 3-4 A away from the host molecule
and rotated at about 36° to produce ten different starting geometries. A full geometry op-
timisation for each of the ten topside complexes were performed and the same was done
for the bottom side approach. The optimised complexes were then recorded according to
their relative energies.164
Since extraction study data of macrocycle 4 and racemic a-methylbenzylamine as guest
has been reported,34 it was decided to perform PM3 calculations on this system and use it
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as a "benchmark" for the calculations of the other systems.
The calculation results (see table 1) for 4 imply that the S-u-methylbenzylamine is pre-
ferred over R-u-methylbenzylamine by 2.4 kcal mor l . The S-u-methylbenzylamine is
predicted to bind preferentially to the topside by ca. 1.3 kcal. mor l . This observation is
consistent with the extraction study data that found macrocycle (R)-4 to selectively
transport S-u-methylbenzylamine in 78.7 % enantiomeric excess.
Table 1: Relative energies (kcal. mor l ) for PM3 calculations of macrocycle (R)-4 with
guests (R) / (S)-u-methylbenzylamine
I R-u-methylbenzylamine S-u-methylbenzylamine
Topside Bottomside TODside Bottomside
2.4 4.1 0.0 2.8
5.0 4.1 3.0 4.0
5.1 4.1 4.1 4.8
5.5 5.8 4.1 5.2
5.6 6.9 5.1 5.2
6.4 7.2 5.5 6.0
6.6 7.6 6.7 6.3
6.6 7.8 7.9 6.3
6.6 8.1 8.1 6.5
7.1 8.5 9.3 7.0
Table 2: Relative energies (kcal. mor l ) for PM3 calculations of macrocycle (R)-57 with
guests (R) / (S) -u-methylbenzylamine
R-u-methylbenzylamine S-u-methylbenzylamine
Topside Bottomside Topside Bottomside
1.2 7.0 0.0 0.7
1.5 7.1 1.1 3.8
2.0 7.5 1.7 5.3
5.2 7.5 2.0 5.9
i 3.0 8.5 2.6 7.9
i 3.0 11.0 2.8 10.8
14.4 12.3 2.9 11.6
4.8 12.5 3.3 14.1
6.6 10.3 6.0 14.4
7.8 16.6 6.5 17.7
Table 2 represents the relative energies of complexes formed between macrocycle 57 and
(R) or (S)-u-methylbenzylamine in kcal mor'. (S)-u-methylbenzylamine is preferred
over (R)-u-methylbenzylamine by 1.2 kcal mor l , which indicates moderate enantiose-
lectivity when compared to the host 4. There is moderate preference for the topside ap-
proach of the guest (0.7 kcal mor l ). The structural conformation for the most stable
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complex fonned between macrocycle (R)-57 with guest (S)-a-methylbenzylamine is
shown in figure 5. The only sign of hydrogen bonding is between a carbonyl oxygen
atom of the crown and a quaternary ammonium hydrogen atom of the guest.
Figure 5: Structural conformation of the most stable complex formed between macrocy-
cle (R)-57 and guest (S)-a-methylbenzylamine. •
Table 3: Relative energies (kcal. mor l ) for PM3 calculations of macrocycle (R)-57 with
guests (R) / (S)-phenylglycinol with hydroxyl group facing away from the
crown
(R)-phen vlelvcinol (S)-phen lelvcinol
Topside Bottomside Topside Bottomside
3.7 8.4 2.7 0.0
3.8 8.5 3.5 4.7
3.8 8.8 5.1 7.6
3.9 9.0 6.8 8.5
4.1 9. ] 7.0 8.8
5.6 10.3 7.0 9.4
6.5 10.8 7. ] 15.2
6.9 15.3 8.2 15.2
10.4 15.9 8.4 16.7
11.5 19.1 9.3 23.5
* All structures available on CD in pdb format
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Table 4: Relative energies (kcal. mor l ) for PM3 calculations of macrocycle (R)-57 with
guests (R) / (S)-phenylglycinol with hydroxyl group facing towards the crown
(R)-phen h!lvcinol (S)-phen b~lycinol
Topside Bottomside Topside Bottomside
0.6 4.8 0.0 4.2
2.1 8.2 0.3 6.1
2.4 8.4 0.4 7.7
2.4 9.1 0.5 10.5
3.1 9.1 1.9 11.0
3.8 10.1 3.0 12.4
4.9 10.6 4.0 15.6
10.4 15.3 5.2 16.5
10.6 15.9 6.4 17.8
11.3 19.2 10.5 19.3
Tables 3 and 4 gives the relative energies of complexes formed between macrocycle 57
and (R) or (S)-phenylglycinol. Table 3 represents complexes in which the OH group of
the phenylglycinol is pointing away from the macrocycle and the NH3 group towards the
macrocycle. Table 4 represents the complexes in which the OH and NH3 groups of the
glycinol are pointing towards the macrocycle. Tables 3 and 4 indicate that the (S)-
phenylglycinol is favoured over (R)-phenylglycinol by 3.7 and 0.6 kcal mort respec-
tively. These calculations imply that there will be greater enantiomeric recognition with
racemic phenylglycinol (3.7 kcal mor l ) as a guest, compared to racemic a-methylbenzyl
amine (1.1 kcal mor l ). Figures 6 and 7 are the structural conformations for the most sta-
ble complexes formed between (R)-57 with guest (S)-phenylglycinol (OH group facing
away and towards the crown respectively). Figure 6 implies that there is significan't hy-
drogen bonding between the quaternary ammonium hydrogen atoms of the guest and a
carbonyl oxygen atom, an ether oxygen atom and an amide hydrogen atom of the host. In
this conformation, the OH group of the phenylglycinol does not participate in hydrogen
bonding with any part of the guest. In figure 7, the hydroxyl hydrogen atom of the
phenylglycinol forms a hydrogen bond with a carbonyl oxygen atom of the crown. Two
of the quaternary ammonium hydrogen atoms of the guest form hydrogen bonds with two
of the carbonyl oxygen atoms of the crown.
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Figure 6: Structural conformation of the most stable complex formed between macrocy-
cle (R)-57 and guest (S)-phenylglycinol with the OH group facing away from
*the crown.
Figure 7: Structural conformation of the most stable complex formed between macrocy-
de (R)-57 and guest (S)-phenylglycinol with the OH group facing towards
from the crown.*
* All structures available on CD in pdb format
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Table 5: Relative energies (kcal. marl) for PM3 calculations of macrocycle (S)-66 with
guests (R) / (S) -a-methylbenzylamine
R-a-methylbenzylamine S-a-methylbenzylamine
Topside Bottomside Topside Bottomside
13.6 1.2 0.0 17.9
14.1 1.8 1.5 17.9
14.7 1.9 5.8 19.6
14.9 1.9 6.0 21.4
15.3 2.2 6.4 21.6
15.6 5.6 6.7 22.9
16.8 9.8 7.9 23.7
17.5 10.2 9.5 24.8
17.9 15.6 10.6 26.4
17.9 18.6 11.9 30.4
Table 5 gives the relative energies of complexes formed between macrocycle 66 and (R)
or (S)-a-methylbenzylamine. (S)-a-methylbenzylamine is preferred over (R)-a-meth-
ylbenzylamine by 1.2 kcal marl, which indicates great enantioselectivity. The structural
conformation for the most stable complex formed between macrocycle (R)-66 with guest
(S)-a-methylbenzylamine is shown in figure 8. It implies that two of the quaternary
ammonium hydrogen atoms of the guest form hydrogen bonds with two carbonyl oxygen
atoms of the crown.
Figure 8: Structural conformation of the most stable complex formed between macrocy-
de (S)-66 and guest (S)-a-methylbenzylamine. •
* All structures available on CD in pdb format
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Table 6: Relative energies (kcal. mor l ) for PM3 calculations of macrocycle (S)-66 with
guests (R) / (S)-phenylglycinol with hydroxyl group facing away from the
crown
(R)-phen vlglycinol (S)-phen Iglycinol
Topside Bottomside Topside Bottomside
1.1 0.7 0.0 4.8
1.5 5.8 0.8 6.5
1.8 8.7 1.3 9.3
2.6 9.4 1.5 9.7
3.0 9.7 1.9 10.2
3.2 10.6 2.1 10.4
3.3 11.4 2.2 10.5
6.7 11.7 4.4 10.8
6.8 11.9 4.6 11.0
7.0 12.5 5.0 11.5
Table 7: Relative energies (kcal. mor l ) for PM3 calculations of macrocycle (S)-66 with
guests (R) / (S)-phenylglycinol with hydroxyl group facing towards the crown
(R)-phen Iglycinol (S)-phen Iglycinol
Topside Bottomside Topside Bottomside
1.1 6.0 0.0 9.2
2.3 9.4 1.0 9.7
3.1 10.0 1.9 9.9
3.5 10.1 2.0 10.2
3.9 10.5 2.2 10.3
4.7 11.1 2.6 11.2
4.8 11.6 2.8 11.6
6.3 11.6 2.9 11.8
6.5 12.7 3.1 12.0
8.4 12.9 5.0 12.6
Tables 6 and 7 gives the relative energies of complexes formed between macrocycle 66
and (R) or (S)-phenylglycinol. Table 6 represents complexes in which the OH group is
pointing away from the crown and table 7 represents the complexes in which the OH
group is pointing towards the crown. Tables 6 and 7 indicate that the (S)-phenylglycinol
is favoured over (R)-phenylglycinol by 0.7 and 2.1 kcal mor l respectively and the com-
plex with the OH facing towards the crown is favoured by 0.8 kcal marl over the com-
plex where the OH is facing away from the crown. These calculations imply that there
will be greater enantiomeric recognition with racemic phenylglycinol (2.1 kcal morl) as
guest, compared to racemic u-methylbenzylamine (1.2 kcal mor\ Figures 9 and 10 are
the structural conformations for the most stable complexes formed between (S)-66 with
guest (S)-phenylglycinol (OH group facing. away and towards the crown respectively).
Figure 9 implies that there is significant hydrogen bonding between the quaternary am-
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monium hydrogen atoms of the guest and two carbonyl oxygen atoms and an ether oxy-
gen atom the host. In this conformation, the OH group of the phenylglycinol does not
participate in hydrogen bonding with any part of the guest. In figure 10, the hydroxyl
hydrogen atom of the phenylglycinol forms a hydrogen bond with a carbonyl oxygen
atom of the crown. The quaternary ammonium hydrogen atoms of the guest form hydro-




Figure 9: Structural conformation of the most stable complex formed between macrocy-
cle (S)-66 and guest (S)-phenylglycinol with the OH group facing away from
the crown...
Figure 10: Structural conformation of the most stable complex formed between macro-
cycle (S)-66 and gues*t (S)-phenylglycinol with the OH group facing to-
wards from the crown.
* All structures available on CD in pdb format
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In the systems studied, u-methylbenzylamine fonned only one hydrogen bond with the
host macrocycle as compared to phenylglycinol, which fonned at least three hydrogen
bonds with the host macrocycle. From the above study it can be concluded that greater
enantiomeric discrimination is observed in systems that fonn a larger number of hydro-
gen bonds between the host and guest.
Using macrocycle 4 as a benchmark (since extraction study results are published) we
found that a 78% enantiomeric recognition for u-methylbenzylamine corresponds to a
calculated relative complexation energy of 2.4 kcal mor l . Although novel macrocycles
57 and 66 exhibit weaker enantiomeric recognition with u-methylbenzylamine, it can be
concluded that they would exhibit promising enantiomeric discrimination with phenyl-




Establishing a method for the efficient incorporation of sterically hindered amino acids
into peptides via solid phase peptide synthesis (SPPS) is an important topic in peptide
chemistry. The incorporation of the TRIS amino acid into a peptide via Fmoc SPPS has
been accomplished using an acid fluoride method. This method normally makes use of
diisopropylethylamine (OlEA) as HF scavenger when incorporating sterically hindered,
non-cage amino acids, like a-aminoisobutyric acid, into peptides. The use of OlEA re-
sulted in premature deblocking of the Fmoc protecting group (base labile) in the case of
the TRIS amino acid. Pyridine was proven to be a better scavenger for this purpose since
it was not basic enough to cause deprotection of the Fmoc group. This discovery could
prove to be very important with respect to solid phase peptide synthesis of sterically hin-
dered amino acids since there have been numerous reports of premature deblocking when
OlEA was used as the scavenger. Qualitative proof for the success of this method comes
in the form of ninhydrin Tests and crude mass spectra data. Future work will involve
determining the efficiency of this method with the use of HPLC and NMR instruments.
An efficient procedure has been established for the synthesis of PCU cage annulated, chi-
ral crown ethers containing amino acids as the source of chirality. Similar PCU crown
ethers have never been synthesised via ring closure with diacid dichlorides and diamines
and non-PCU crown ethers gave relatively poor yields « 20%). In this study the PCU
diacid was synthesised in excellent yields (> 80%) and converted to the corresponding
diacid dichloride in equally good yields (> 80%). The use of dry, non-polar solvents
(toluene or benzene) and high dilution conditions (l mmol. dm-3), have proven to be
some of the determining factors in obtaining relatively good yields (> 30%). The rigidity
of the cage may also be assisting in tying up the loose ends of the crown ethers. Posi-
tioning of the chiral centres closer to the cage successfully induced chirality into the ten
inducible centres of the PCU cage. resulting in an increase in the overall chirality of the
macrocycle.
Enantiomeric recognition of the chiral PCU cage crown ethers was studied using NMR,
fluorescence and computational methods. The aim of this study was to get familiar with
different techniques available for enantiomeric recognition. Efficiency of the enantiom-
eric recognition capabilities of the novel crown ethers was compared with a PCU cage
annulated crown ether for which extraction study data already existed. The known and
novel crown ethers showed no significant complexation activity in the NMR and Fluores-
cence studies. The computational studies indicate that greater enantiomeric recognition
occurs between the novel crown ethers synthesised in this study and various guests, as
compared to the known crown ether with the same guests. Future work will involve cali-
brating extraction studies with computational studies.
Synthesis of sterically hindered amino acids, like cage amino acids, requires elevated
temperatures and pressures with respect to non-sterically hindered amino acids. An effi-
cient method has been established for the synthesis of racemic pentacycIo-undecane
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(peD) and trishomocubane (TRIS) cage amino acids via a hydantoin route. Future work
will involve synthesis of the enantiomerically pure cage amino acids with the use of en-
zymes (hydantoinases). Hydantoinases enantiomerically catalyse the hydrolysis of hy-




Melting points (uncorrected) were determined using a Mel-Temp apparatus in sealed
capillary tubes with the head space above the sample filled with a glass rod to minimise
sublimation. High-resolution mass spectral data reported herein were obtained by Profes-
sor Jennifer S. Brodbelt at the Mass Spectrometry Facility at the Department of Chemis-
try and Biochemistry, University of Texas at Austin by using a ZAB-E double sector
high-resolution mass spectrometer (Micromass,.Manchester, England) that was operated
in the chemical ionisation mode. NMR spectra were recorder on a Varian Gemini-200
and a Varian Gemini-300 spectrophotometer.
Synthesis of Pentacyclo[5.4.0.02,6.03,10.05,9]undecane-S,II-dione (31)76.77
p-Benzoquinone (240g, 2.22mol) in methanol (lL) was cooled to -70°C via application
of an external dry ice-acetone cold bath. To this was added, over 8 hours, with stirring a
solution of freshly cracked cyclopentadiene (l71.6g, 2.6 mol) in cold methanol (200ml).
The reaction mixture was allowed to warm gradually to room temperature with stirring.
The product was filtered and recrystallized from n-hexane to yield the adduct as yel-
lowish-green crystals 30 (280g, 68%).
The above adduct (30, 60g) was dissolved in 600ml acetone and irradiated with a 500W
mercury lamp until the TLC (4: 1 hexane:ethyl acetate) indicated the absence of starting
material (6 - 8 hours). The solvent was evaporated to give the product as a colourless
microcrystalline solid 31 (52g, 86%), m.p 233°C.
The IR and NMR data were identical to an authentic sample.
Synthesis of the Ketal (31)77
A mixture of the dione (99.2g, 0.5731mol), ethylene glycol (44ml, 0.78mol) and
p-toluenesulfonic acid (3.31 g, catalytic amount) in benzene (600ml) was refluxed (Dean
Stark trap) with stirring for 5 hours. The reaction mixture was cooled and slowly poured
into 500ml of ice cold 10% aqueous NaZC03, extracted with dichloromethane (500ml x
2) and the combined extracts were dried over anhydrous MgS04. Evaporation of solvent
followed by recrystallisation of the crude residue yielded the mono-ketal 31 (93.2g,
74.62%), as colourless crystals.
The IR and NMR data were identical to an authentic sample.
Synthesis of 11-Hydroxypentacyclo [5.4.0.02,6.03,10.05,9]undecan-S-one (34)77,78
To a suspension of LiAlH4 (l2.08g, 0.3183 mol) and dry ether (2 L) was added, under
argon very slowly, the ketal 32 (92.5g, 0.4243 mol). The mixture was then refluxed for
l2 hours. The reaction was quenched by drop-wise addition of saturated NaZS04 solution
with vigorous stirring. The white slurry thus formed was filtered and washed with ether.
The filtrate was concentrated and dried to give the hydroxy-ketal 33 (89.5g, 96%).
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A mixture of the hydroxy-ketal 33 (89.5g, 0041 mol), THF (200ml), water (lOOml) and
concentrated HCI (l5ml) was stirred at room temperature for 18 hours. The mixture was
diluted with water (500ml) and extracted with dichloromethane (4 x 300ml). The com-
bined organic phase was washed with water (2x), then with saturated aqueous NaHC03
solution (2x), dried over anhydrous Na2S04 and concentrated to give the product as white
solid 34 (62.7g, 76.5%), m.p. 255°C.
The IR and NMR data were identical to an authentic sample.
Synthesis of Pentacyclo[5.4.0.02,6.03,IO.05,9]undecan-8-o1 (35)77
A mixture of the hydroxy-ketone 34 (l3g, 0.074 mol) and hydrazine hydrate (20ml, 98%,
0.56 mol) in diethylene glycol (200ml) was maintained at 120°C for 2hrs. The mixture
was allowed to cool down to 80°C after which KOH (lOg) was added and the excess hy-
drazine hydrate and water was distilled off until the temperature reached 185°C. The re-
action mixture was refluxed for 3hrs at 185°C, cooled, diluted with water (300ml), ex-
tracted with dichloromethane. The combined organic phase was concentrated and dried.
The residue was purified by steam distillation to yield the alcohol 35 (11.2g, 56.3%), m.p.
231-232°C.
The IR and NMR data were identical to an authentic sample.
Synthesis of Pentacyclo[5.4.0.02,6.03,IO.05,9]undecan-8-one (22)77
To a mixture of Cr03 (l4g, 0.14 mol) in water (l5ml) and acetic acid (l50ml, 98%), was
added the alcohol 35 (lOg, 0.0625 mol) in acetic acid (50ml) drop-wise over a period of
10 minutes with stirring. The reaction mixture was stirred at 90°C for 5 h, cooled, diluted
with water (600ml) and extracted with CH2Ch (3 x 300ml). The organic extract was
washed successively with water (2 x 500ml), saturated aqueous NaHC03 (2 x 500ml),
water (2 x 500ml) and dried over anhydrous MgS04. Removal of the solvent gave the
crude mono-ketone 22 which was purified by steam distillation to give the product (7,5g,
76%), m.p. 194-195°C.
The IR and NMR data were identical to an authentic sample.
Synthesis of the PCU-hydantoin (24)73
A glass pressure reaction vessel was charged with a mixture of the mono-ketone 22 (lg,
6.2 mmol), NaCN (lg, 20 mmol), (NH4hC03 (2g, 20 mmol), EtOH (lOml) and concen-
trated NH40H (l5ml). After heating at 60°C for 2 hours, 100°C for 2 hours and 120°C
for 3 hours, the reaction mixture was cooled, diluted with water (lOOml) and the solids
were collected by suction filtration. The solids were washed with H20, acetone, and
Et20 and air-dried to yield dense white crystals 24 (lAg, 98%), m.p. 230°C.
The IR and NMR data were identical to an authentic sample.
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Synthesis of the PCU-Amino Acid (6)
A suspension of the hydantoin 24 (l g, 4.3 mmoI) in 1.25N NaOH solution (50ml) was
heated in a pressure vessel for 12 hours with stirring at l70°e. The cooled mixture was
diluted with water (200mI) and the solution acidified with concentrated HCI. The solu-
tion was filtered, concentrated (-lOOmI) under reduced pressure and neutralised with
NaOH solution, whereupon fine white crystals were precipitated. The product was col-
lected under suction, recrystallised from water, washed with acetone and diethyl ether,
and air-dried to give the product 6 (O.5g, 56%).
The IR and NMR data were identical to an authentic sample.
Synthesis of Pentacyclo[6.3.0.02,6.03,10.05,9]undecan-4-o1 (37)77
The alcohol 35 (31.2g, 0.195 mol) in glacial acetic acid (360ml) containing conc. H2S04
(9g) was refluxed for 6hrs. (The reaction mixture turned dark in colour after a few min-
utes of refluxing.) The reaction mixture was cooled, diluted with water (l500ml) and
extracted with CH2CIz. The dichloromethane extract was washed successively with water
and sat.aq. NaHC03and decolourised with activated charcoal. Removal of the solvent
gave the crude acetate 36 as dark yellow oil that was stirred overnight in a mixture of
methanol (330ml) and K2C03 (l8g). The reaction mixture was concentrated, the residue
obtained was diluted with water and the solid that separated was filtered and dried to af-
ford pure alcohol 37 (20.6g, 66%) as a white solid, m.p. 167-168°e.
The IR and NMR data were identical to an authentic sample.
Synthesis of Pentacyclo[6.3.0.02,6.03,10.05,9]undecan-4-one (25)77
To a mixture of Cr03 (32g, 0.32 mol) in water (27ml) and acetic acid (320ml), was added
the alcohol (20.6g, 0.13 mol) in acetic acid (lOOml) drop-wise over a period of 10 min-
utes with stirring. The reaction was then stirred at 90°C for 6h, cooled, diluted with wa-
ter (1.2 L) and extracted with dichloromethane. The organic extract was washed succes-
sively with water (3 x 500ml), saturated sodium bicarbonate solution (3 x 500mI), and
water (3 x 500ml). Removal of the solvent gave the product 25 (l6.2g, 79.6%) as
colourless microcrystalline solid.
The IR and NMR data were identical to an authentic sample.
Synthesis of the Trishomocubane hydantoin (26)
A mixture of the monoketone 25 (lg, 6 mmoI), NaCN (lg, 20 mmol), (NH4)zC03 (2g, 20
mmoI), EtOH (lOrn!) and concentrated NH40H (l5ml) was taken in a glass pressure re-
action vessel. After heating at 60°C for 2 hours, 100°C for 2 hours and 120°C for 3 hours,
the reaction mixture was cooled, diluted with water (lOOml) and the solids were collected
under suction. The solids were washed with H20, acetone, and Et20 and air-dried to
yield dense white crystals 26 (lAg, 98%). The analytical sample was recrystallised from
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tetrahydrofuran: m.p. 324.5-325°C; IR (KBr): Vmax 3314, 3161, 1766, 1720, 1403, 1286
cm-'; 'H-NMR [DMSO, 200 MHz]: DH 1.15-1.46 (m, 4H), 1.86-2.05 (m, 2H), 2.07-2.26
(m, 4H), 2.46 (br s, 1H), 2.85 (br s, 1H), 7.89 (s, 1H, D20 exchangeable), 10.55 (s, IH,
D20 exchangeable); l3C-NMR [DMSO, 50 MHz]: Dc 32.25 (t), 32.78 (t), 41.51 (d), 42.06
(d), 42.99 (d), 44.96 (d), 45.97 (d), 46.41 (d), 54.14 (d), 54.98 (d), 72.78 (s), 156.33 (s),
176.74 (s); CI MS: Calc. for C13H1SN202 [M+H+] rn/z 231.1133, Found [M+H+]
231.1133.
Synthesis of the Trishomocubane-Amino Acid (7)77
A suspension of the hydantoin 26 (lg, 4.3 mmol) in 1.25N NaOH solution (50m!) in a
pressure vessel was heated for 12 hours with stirring at 170°C. The cooled reaction
mixture was diluted with water (200ml) and acidified with concentrated HCI. The solu-
tion was filtered, concentrated (-1 OOml) and neutralised with NaOH solution, whereupon
fine white crystals precipitated. The product was collected, recrystallised from water,
washed with acetone and diethyl ether, and air-dried to give the product 7 (0.5g, 56%).
IR (KEr): Vmax 3250, 3204, 2955, 2854, 2735, 1579, 1497, 1386 em-I.
Fmoc TRIS Amino Acid (27)
To a solution of the amino acid 7 (O.lg, 4.88 x 10-4 moles) in dioxane (7.5ml) and 10%
Na2C03 (20m!) was added slowly with stirring and ice-bath cooling a solution of 9-fluo-
renylmethyl chloroformate (FMOC) (0.151g, 5.8 x lO-4moles) in dioxane (5ml) for 4
hours and at room temperature for 8 hours, diluted with water (50ml) and extracted with
diethyl ether (2 x 50m!). The aqueous layer was cooled in an ice-bath and acidified to pH
2 with concentrated HCI. Extraction with ethyl acetate (3 x 50m]) gave the product 27 as
a white solid (0.152g, 72%), m.p.213-214°C; IR (KBr): Vmax 3360, 2952, 1748, 1702,
1294,1231,1041 cm-'; 'H NMR [DMSO, 200MHz]: DH 1.15-1.50 (m, 4H), 1.90-2.30 (m,
7H), 2.47 (m, IH), 3.35 (s, IH, D20 exchangeable), 4.10-4.43 (m, 3H), 7.22-8.08 (m,
8H), 12.17 (s, IH, D20 exchangeable); l3C NMR [DMSO, 50 MHz]: Dc 31.7 (t), 32.7 (t),
42.5 (d), 42.6 (d), 42.8 (d), 43.8 (d), 46.1 (d), 46.4 (d), 46.7 (d), 52.8 (d), 53.3 (d), 65.1
(s), 68.6 (t), 120.0 (d), 125.1 (d), 125.2 (d), 126.9 (d), 127.9 (d), 140.6 (s), 140.7 (s),
143.7 (s), 143.8 (s), 155.3 (s), 174.0 (s); CI MS: Calc. for C27H26N04 [M+H+] rn/z
428.1861, Found 428.1860
Fmoc TRIS Amino Acid Fluoride (40)
Cyanuric fluoride (40.5ul, 4.68 x lO-4moles) was added to a suspension of Fmoc TRIS
Amino Acid 27 (0.2g, 4.68 x 1O-4moles) in dry CH2Ch (50ml) and dry pyridine (37.8ul,
4.68 x 10·4moles), and stirred under argon for 5 hours. The mixture, from which a water-
soluble white precipitate had settled, was extracted with ice water (2 x 20ml). The or-
ganic phase was dried over MgS04 and concentrated to give a white solid that was re-
crystallised from CH2Ch/hexane to give the pure acid fluoride (0.188g, 90%), m.p. 84-
85°C; IR (KBr): Vmax 3346, 2966, 1829, 1724, 1504, 1457, 1277 em-I; IH NMR [CDC!),
200 MHz]: DH 1. 18-1.16 (m, 4H), 1.96-2.46 (m, 7H), 2.73 (br s, IH), 4.22 (t, J =6.6 Hz,
IH), 4.75 (d, J =6.2 Hz, 2H), 5.38 (s, IH, DzO exchangeable), 7.25-7.48 (m, 4H), 7.59
(d, J =7Hz, 2H), 7.77 (d, J =7Hz, 2H); l3C NMR [CDCl), 50 MHz]: Dc 32.0 (t), 33.0 (t),
42.7 (d), 42.9 (d), 43.2 (d), 44.2 (d), 46.9 (d),·47.0 (d), 47.2 (4), 53.7 (d), 54.1 (d), 66.7
(t), 68.1 (s), 69.2 (s), 119.3 (d), 124.8 (d), 127.0 (d), 127.6 (d), 141.3 (s), 143.5 (s), 155.2
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(s), 158.6 (s), 166.0 (s); 19F NMR [CDC!], 282 MHz]: bF -180.3; CI MS: Calc. for
C27H2SN03F [M+H+] m/z 430.1818, Found 430.1810
C I" f GI" t W R" 80,81,82,83oup mg 0 ycme on 0 ang- esm
The Fmoc Glycine 41 (0.6g, 2 x 1O-3moles), DIPCDI (0.254g, 2 x 1O-3moles) and 1-
hydroxybenzotriazole (0.270g, 2 x 1O-3moles) was added at room temperature to the resin
(0.5g, 6.25 x 1O-4moles) in dimethylformamide (DMF). The mixture was shaken
occasionally for 12 hours and then washed.
Deprotection of Fmoc group
The Fmoc group was cleaved by shaking the resin with 20% piperidine in DMF for 30
minutes. Kaiser Test should show positive.
Washing procedure for Solid Phase Peptide Synthesis
The resin was washed using DMF (5 x lOml, 30 seconds), isopropanol (3 x lOml, 30 sec-
onds) and DMF (3 x lOml, 30 seconds).
Coupling of Fmoc TRIS Acid Fluoride (40) using Diisopropylethylamine (DIEA) as
HF scavenger .
The amino acid fluoride 40 (0.670g, 1.56 x 1O-3moles) and DIEA (271 ul, 1.56 x 10-
3moles) was added to the resin 42 in DMF and shaken every 30 minutes for 6 hours.
Resin was washed and showed a positive Kaiser Test.
Coupling of Fmoc TRIS Acid Fluoride using pyridine as HF scavenger
(Dipeptide 43)
The amino acid fluoride 40 (0.670g, 1.56 x 10-3 moles) and pyridine (151 ul, 1.87 x 10-
3moles) was added to the resin 42 in DMF and shaken every 1 hour for 24 hours. Resin
was washed and showed a negative Kaiser Test. The Fmoc group was cleaved by shaking
the resin with 20% piperidine in DMF for 30 minutes. Kaiser Test showed positive. The
dipeptide 43 was cleaved as described in the general procedure below.
FAB MS Calc. for CI4HI8N203 [M+H+] rn/z 263, Found 263
Coupling of Fmoc Glycine Acid Fluoride to the TRIS Amino Acid containing resin
(Tripeptide 45)
The Fmoc Glycine Acid Fluoride 44 (0.600g, 2.00 x 1O-3moles) and pyridine (162 ul,
2.00 x 1O-3moles) was added to the resin containing the dipeptide 43 in DMF and shaken
occasionally for 24 hours. Resin was washed and showed a negative Kaiser Test. The
Fmoc group was cleaved by shaking the resin with 20% piperidine in DMF for 30
minutes. Kaiser Test showed positive. The tripeptide 45 was cleaved as described in the
general procedure below.
FAB MS Calc. for Cl6H21N304 [M+H+] m/z 320, Found 320
Cleavage of the peptide from the resin (Novabiochem General Procedure)
Resin was washed several times with CH2Ch, methanol and Et20, and dried overnight on
a vacuum pump. The dry resin was placed in a flask and the cleavage mixture (95% Tri-
fluoroacetic acid (TFA), 2.5% H20, 2.5% triisopropylsilane) added. The flask was left at
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room temperature for 5 hours with occasional stirring. The resin was removed by filtra-
tion and washed twice with TFA. The filtrate was concentrated by blowing air over it
while continuously adding Et20 .
(R)-(+)-2-Phenylglycinol (62) 145
To an ice cooled suspension of LiAIH4 (2g) in dry THF (l50ml) was added drop-wise the
(R)-(+)-2-phenylglycine methyl ester 61 (3g, 18.18mmol) in dry THF (lOOml). The
mixture was refluxed under argon for 2 hours and quenched with saturated Na2S04 solu-
tion (lOml). The white precipitate was filtered and washed successively with THF, the
filtrate was dried over Na2S04 and concentrated.
The product was recrystallised from toluene to yield the (R)-(+)-2-phenylglycinol 62
(1.6g, 65%): m.p. 69-71 °c (lit. 72_73°C)145
The IR and NMR data were identical to an authentic sample.
exo-8-exo-ll-Diallylpentacyclo[5.4.0.02,6.03,10.05,9]undecane-endo-8-endo-ll-diol
(51)109 .
A solution of dione 31 (58.47 g, 336 mmol) in dry THF (500 mL) was added dropwise
over 2 hours to a mechanically stirred suspension of freshly prepared_allylmagnesium
bromide (2.2 L of 0.392 M in dry THF; excess) under argon at O°c. After the addition
had been completed, the external ice-water bath was removed, and the reaction mixture
was allowed to warm gradually to ambient temperature while stirring under argon during
24 h. The reaction was quenched via addition of saturated aqueous NH4CI (until pH is
6-7), the layers were separated, and the aqueous layer was extracted with EtOAc (2 x 500
mL). The combined organic extracts were dried (MgS04) and filtered, and the filtrate was
concentrated in vacuo. The residue was recrystallized from hexane, thereby affording
pure 51 (78.89 g, 91 %) as a colourless microcrystalline solid: m.p. 82-83 °C; IR (KBr):
Vmax 3169, 2976.1639 cm'l ; 'H-NMR [CDCh, 200 MHz]: 8H 1.05 (AB, JAB =10.8 Hz, 1
H). 1.49 (AB. JAB = 10.8 Hz, 1 H), 1.97-2.24 (m, 6 H), 2.30-2.61 (m, 6 H), 5.01 (dd, J =
8.0 & 2.6 Hz. 2 H). 5.04 (dd. J = 16.85 & 2.6 Hz, 2 H), 5.90 (m, 2 H), 6.52 (br s, 2 H);
13C-NMR [CDCh, 50 MHz]: Dc 33.9 (t), 40.0 (d), 42.8 (d), 44.0 (d), 44.1 (t), 49.1 (d),
77.2 (s), 117.5 (t), 133.8 (d). CI MS: Calc for C 17H220 2: [M + H]+ mlz 259.16981.
Found: [M + H]+ mlz 259.16994. Anal. Calcd for C17H220 2: C, 79.03; H, 8.58. Found: C,
79.14; H, 8.42.
3,5_Diallyl_4_oxahexacyclo[5.4.1.02,6.03,10.05,9.08,1l] dodecane (52)109
A solution of 51 (61 g, 0.236 mol) and TsOH (l.5 g, 0.79 mmol, catalytic amount) in
benzene (1.2 L) was refluxed in a Dean-Stark apparatus and the resulting water was re-
moved azeotropically. After every 12 hours, additional TsOH (500 mg) was added. When
TLC indicated the absence of 51 (72 hours). the reaction mixture was allowed to cool
gradually to ambient temperature and washed sequentially 10% aqueous NaHC03 (l00
mL), water (l00 mL) and brine (l00 mL). The organic layer was dried (MgS04) and fil-
tered, and the filtrate was concentrated in vacuo. The residue was purified via column
chromatography on silica gel by eluting with 5% EtOAc-hexane. Pure 52 (46.53 g, 82%)
was thereby obtained as a colourless oil; IR (neat): Vmax 3075, 2965, 1640,997,910 cm'l;
IH-NMR (CDC!}): DH 1.46 (AB, JAB = 10.2 Hz, 1 H), 1.82 (AB, JAB = 10.2 Hz, 1 H),
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2.35 (br s, 2 H), 2.45-2.65 (m, 10 H), 5.01 (dd, J = 9.8 & 2.2 Hz, 2 H), 5.07 (dd, J = 15.4
& 1.4 Hz, 2 H), 5.78 (m, 2 H); 13C NMR (CDCh): be37.5 (t), 41.7 (d), 43.3 (t), 44.5 (d),
47.8 (d), 58.6 (d), 95.1 (s), 116.8 (t), 134.4 (d). CI MS: Calc. for C17H200: [M + H]+ rn/z
241.1592. Found: [M + H]+ rn/z 241.1601.
3,5-dicarboxymethyl-4-oxahexacyclo[5.4.1.02,6.03,10.05,9.08,11]-dodecane (59)
A solution of the diene 52 (3.3g) in dry methanol (lOOml) was purged with argon for 20
minutes while cooling in a dry ice-acetone bath. Ozone was bubbled into the mixture
until the blue-purple colour persisted indicating the presence of excess ozone and com-
pletion of reaction. The excess ozone was flushed out with argon and the solvent was
removed under reduced pressure. Hydrogen peroxide (30ml, 30%) was added drop-wise
to a stirred, ice bath cooled mixture of the ozonide and formic acid (21ml). The reaction
was stirred at ambient temperature for 1 hour, refluxed gently for 12 hours and concen-
trated to yield the diacid 59 (2.895g, 76%) as a white solid, m.p. 175-175.5°C; IR (KEr):
Vrnax 3180, 2980, 1720 cm-
I; IH NMR [DMSO, 200 MHz]: bH 1.45 (AB, JAB=lO Hz,
1H), 1.83 (AB, JAs=lO Hz, 1H), 2.36-2.80 (m, 12H), 12.15 (br s, 2H, D20 exchange-
able); 13C NMR [DMSO, 50 MHz]: be 37.94 (t), 41.27 (d), 42.81 (t), 44.04 (d), 47.91
(d), 58.55 (d), 92.56 (s) and 171.40 (s); Anal. Calc. for CIsHI604 C,65.21; H,5.84: Found
C,65.39; H,5.71
(R,R)-1,11-Diamino-l,11-diphenyl-3,6,9-trioxaundecane (63)146
The {R)-amino alcohol 62 (l.476g, 1O.78mmol) in dry THF (50ml) was added drop-wise
at O°C to a stirred suspension of NaH (55-60% in oil, 0.8g) in dry THF (80ml) under ar-
gon. The mixture was stirred at room temperature for 2 hours, treated with the diethylene
glycol bis-toluene-p-sulphonate (2.23g, 5.395mmol) in dry THF (50ml) and stirred at
room temperature for 72 hours. The reaction was quenched with water (60ml) and the
solution concentrated to about 40ml. The concentrate was acidified with HCl (l5%,
50ml), washed with ethyl acetate (3 x 50ml), made basic (Na2C03), and extracted' with
ethyl acetate (3 x 50ml). This extract was dried and evaporated to give the crude diamine
63 as an oil which was suitable for use in the next step, IH-NMR [CDCh, 200 MHz]: bH
7.45-7.19 (m, 2 x C6HS), 4.20 (m, 2 x NCH), 3.65-3.40 (m, 6 x OCH2) and 2.68 (br s, 2 x
NH2).
Synthesis of macrocycle (R,R)-57
To a suspension of the diacid 59 (0.552g, 2mmol) in dry CH2Clz (lOml) was added oxa1-
ylchloride (2ml, 23mmol) drop-wise with stirring under argon. Stirred for a further 5
hours after the reaction became homogeneous and concentrated (using a vacuum pump)
to yield the diacyl choride 60 as a clear oil. Mixtures of the diamine 63 (0.688g, 2mmol)
and N(Et)) (0.56ml) in toluene (250ml) and the diacyl choride 60 (2mmol) in toluene
(250ml) were added simultaneously over 10 hours to toluene (250ml) with stirring at O°C
under argon. The mixture was then stirred at ambient temperature for 1 day and concen-
trated. The product 57 was obtained by chromatography (alumina, 1:5 ethyl acetate: di-
choromethane) and recrystallised from toluene to give clear crystals (0.43g, 37%), m.p.
94-97°C; [a]24D + 6.56° (c=l, CH2Ch); IR (KEr): Vrnax 3343, 3307, 2958, 2870, 1674,
1517, and 1109 cm- I; 'H NMR [CDCh, 200 MHz]: bH 1.49 (AB, JAs=1O.5 Hz, 1H), 1.82
(AB, JAs=1O.6 Hz, 1H), 2.15-2.80 (m, lOH), 2.89 (AB, JAs=15.5 Hz, 1H), 2.98 (AB,
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JAB=14.8 Hz, 1H), 3.45-3.95 (m, 12H), 5.09-5.30 (m, 2H), 7.12-7.53 (m, lOH), 7.65 (d, J
=8.1 Hz, 1H), 7.74 (d, J =8 Hz, 1H); l3C NMR [CDCh, 50 Hz]: Be 39.55 (t), 39.58 (t),
41.00 (d), 41.35 (d), 43.15 (t), 43.68 (d), 43.98 (d), 46.22 (d), 49.76 (d), 52.80 (d), 52.85
(d), 56.36 (d), 60.06 (d), 70.22 (t), 70.89 (t), 70.94 (t), 73.91 (t), 73.94 (t), 93.98 (s),
94.05 (s), 126.62 (d), 127.01 (d), 128.04 (d), 140.25 (s), 140.32 (s), 169.14 (s); CI MS:
Calc. for C3sH41Nz06: [M + H+] 585.2964, Found: [M + H+] 585.2973.
N-Benzyloxycarbonyl-L-proline diester (64)138
In dry CHzCIz (200ml) were dissolved 2,6-pyridinedimethano1 (lg, 7.2 x lO'3mo1es),
benzyloxycarbonyl-L-proline (3.66g, 17 x lO,3moles), 4-(dimethylamino)pyridine (O.4g,
20 x 1O-3moles), and DIPCDI (2.5g, 20 x 1O-3moles). After stirring overnight at room
temperature, the reaction was concentrated and the residue was chromatographed on
silica gel to give a colourless oil 64 (2.7g, 72%).
IH NMR: QH 1.95 (m, 4H), 2.11 (brs, 2H), 2.26 (d, 2 H), 3.64 (m, 4H), 4.51 (m, 2H), 5.11
(m, 6H), 5.27 (d, 2H), 7.26 - 7.56 (m, 13H)
L-Proline diester diamine dihydrobromide l38
N-benzyloxycarbonyl-L-proline diester 64 (lg, 1.87 x lO'3moles) was dissolved in 33%
HBr-HOAc (25ml). The mixture was stirred at room temperature overnight and the pre-
cipitate was filtered and washed with diethyl ether. The product was recovered as a light
yellow powder 65 (0.833g, 90%).
The IR and NMR data were identical to the authentic sample.
S-PhenylGlycine Pyridine Diamine (67)
The (S)-amino alcohol (0.7g, 5.1 x 1O-3moles) in dry THF (50ml) was added drop-wise at
O°C to a stirred suspension of NaH (55 - 60% in oil, 0.45g, 15 x lO'3moles) in dry THF
(80m!) under argon. The mixture was stirred at room temperature for 2 hours, treated
with the 2,6-pyridine dimethylbromide (0.675g, 2.5 x lO'3moles) in dry THF (50ml) and
stirred at room temperature for 72 hours. The reaction was quenched with water (60ml)
and the solution concentrated to about 40ml. The concentrate was acidified with HCI
(l5%, 50ml), washed with ethyl acetate (3 x 50ml), made basic (Na2C03), and extracted
with ethyl acetate (3 x 50ml). This extract was dried and evaporated to give the crude
diamine as a light yellow oil 67 (0.672g, 71 %) which was suitable for use in the next
step. A small amount was chromatographed on alumina for characterisation. [af4o +
40.00°; IR (neat): Vmax 3370, 3061, 3025, 2898, 1585, 1449, 1357, 1104 cm'l; I H-NMR
[CDCh, 200 MHz]: DH 1.91 (s, 4H, DzO exchangeable), 3.46-3.72 (m, 4H), 4.25 (d, J =
3.7 Hz, 1H), 4.29 (d, J =4Hz, 1H), 4.65 (s, 4H), 7.18-7.45 (m, 12H), 7.67 (t, J =7.7 Hz,
1H); l3C NMR [CDCI3, 50 MHz]: Dc 55.4 (d), 73.9 (t), 77.1 (t), 119.9 (d), 126.7 (d),
127.3 (d), 128.3 (d), 137.2 (d), 142.2 (s), 157.7 (s); CI MS: Calc. for C23H27N302: [M +
H+] 378.2181, Found: [M + H+] 378.2175
Synthesis of macrocycle (S,S)-66
To a suspension of the diacid 59 (0.552g, 2mmol) in dry CHzClz (lOml) was added oxalyl
chloride (2ml, 23mmol) drop-wise with stirring under argon. The reaction mixture was
then stirred for a further 5 hours, and concentrated using a vacuum pump to yield the
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diacyl choride 60 as a colourless oil. Mixtures of the diamine 67 (0.755g, 2mmol) and
N(Et)3 (0.56ml) in toluene (250ml) and the diacyl choride 60 (2mmol) in toluene (250ml)
were added simultaneously over 10 hours to toluene (250ml) with stirring at OOC under
argon. The mixture was then stirred at ambient temperature for 1 day and concentrated.
The product was obtained by chromatography (alumina, 1:5 ethyl
acetate:dichloromethane) as white solid 66 (0.3g, 24%), m.p. 89-91°C; [a]24D+ 36.06° IR
(KBr): Vmax 3425, 3327, 2957, 1656, 1523, 1488, 1116 em-I; IH NMR [CDC!), 200
MHz]: bH 1.40 (AB, JAB = 10.6 Hz, IH), 1.75 (AB, lAB = 10.6 Hz, IH), 2.22-2.74 (m,
12H), 3.80-4.00 (m, 4H), 4.66 (t, J = 14.3 Hz, 4H), 5.09-5.23 (m, 2H), 7.12-7.44 (m,
12H), 7.62-7.74 (m, 2H), 7.79 (d, J =7.7 Hz, IH); l3C NMR [CDCh, 50 MHz]: be 39.8
(t), 39.9 (t), 41.3 (d), 41.4 (d), 43.1 (t), 44.1 (d), 44.2 (d), 47.6 (d), 48.9 (d), 53.1 (d), 53.2
(d), 58.0 (d), 59.2 (d), 74.1 (t), 74.2 (t), 74.3 (t), 74.4 (t), 93.7 (s), 93.8 (s), 121.7 (d),
121.8 (d), 126.8 (d), 127.2 (d), 128.2 (d), 137.5 (d), 140.1 (s), 157.4 (s), 157.7 (s), 169.2
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FAB MS of Gly-TRIS-Gly tripeptide (45)
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CI MS of macrocycle 57
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